Savara Inc.
SVRA
$0.07
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Revenue of Savara Inc. (SVRA)
Revenue in 2023 (TTM): $
According to Savara Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Savara Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-44,262,000 | $-59,133,000 | $-54,698,000 | $-54,698,000 |
| 2022 | $ | $-167,000 | $-37,895,000 | $-38,150,000 | $-38,946,000 |
| 2021 | $ | $-367,000 | $-40,365,000 | $-43,014,000 | $-45,296,000 |
| 2020 | $257 K | $221.96 K | $-47,440,000 | $-49,615,000 | $-51,097,000 |
| 2019 | $ | $-1,010,000 | $-77,093,000 | $-78,173,000 | $-105,025,000 |
| 2018 | $ | $-526,000 | $-69,501,000 | $-70,027,000 | $-61,516,000 |
| 2017 | $ | $-363,000 | $-31,907,000 | $-33,431,000 | $-29,797,000 |
| 2016 | $400 K | $400 K | $-10,482,000 | $-11,280,000 | $-10,923,000 |
| 2015 | $54 | $-145,946 | $-39,093,000 | $-39,842,000 | $-39,842,000 |
| 2014 | $1.55 K | $1.55 K | $-28,617,000 | $-28,702,000 | $-28,702,000 |
| 2013 | $ | $ | $-21,440,766 | $-21,480,285 | $-21,480,285 |
| 2012 | $ | $ | $-15,469,445 | $-15,559,489 | $-15,559,489 |
| 2011 | $ | $ | $-13,222,358 | $-13,259,931 | $-13,260,000 |
| 2010 | $488.96 K | $488.96 K | $-8,429,473 | $-8,450,922 | $-8,450,922 |
| 2009 | $300 K | $300 K | $-11,205,957 | $-11,325,058 | $-11,325,058 |
| 2008 | $500 K | $500 K | $-27,141,796 | $-26,647,493 | $-26,647,493 |
| 2007 | $500 K | $500 K | $-24,113,262 | $-22,142,040 | $-22,142,040 |
| 2006 | $ | $ | $-29,155,087 | $29.33 M | $-29,331,773 |
| 2005 | $496.06 K | $496.06 K | $-13,087,441 | $-24,782,646 | $-24,782,646 |
| 2004 | $ | $ | $-6,659,739 | $-2,332,077 | $-6,701,048 |
| 2003 | $ | $ | $-2,321,721 | $-2,332,077 | $-2,332,077 |
| 2002 | $ | $ | $-1,716,778 | $-2,053,303 | $-2,105,727 |
| 2001 | $ | $ | $2.72 M | $-16,358,791 | $-16,339,120 |
| 2000 | $ | $ | $-1,811,168 | $ | $-3,701,084 |